100 results on '"Huang, D."'
Search Results
2. LBA6 Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study
3. 423P Fruquintinib plus sintilimab in refractory repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Preliminary clinical results and biomarker analyses from a phase II study
4. 1017P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
5. 1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study
6. 2P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
7. 1P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)
8. 150P Subgroup analysis of ORIENT12: Efficacy of sintilimab in combination with gemcitabine and platinum-based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancer
9. 479P Difference gene mutations among CRC patients with MSS and MSI-H types in China
10. 458P Circulating tumor DNA analysis predicting recurrence risk in patients with stage I-III colorectal cancer
11. 1219P Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004
12. 1280P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
13. 1370TiP Befotertinib versus icotinib as first-line treatment in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer: A multicenter, randomized, open-label, controlled phase III study
14. 1250P Differences of immune microenvironment among NSCLC patients with various KRAS mutation types
15. 1284P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
16. 1290P RATIONALE 304: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for non-squamous (non-sq) non-small cell lung cancer (NSCLC) in patients (pts) who are smokers vs non-smokers
17. 1998P Antitumor activity and safety profile of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy (TRACES): Updated results from TRACES
18. LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
19. 1439P Brain radiotherapy combined with camrelizumab and platinum-based chemotherapy as first-line treatment for advanced NSCLC with brain metastases: A multicenter, open-label, single-arm, phase II study
20. 1378P Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
21. P-217 A retrospective, pathologist-based assessment of immunohistochemistry assay for CLDN18.2 expression in digestive system adenocarcinoma
22. P-171 Digital image analysis of Ki67 heterogeneity of pancreatic neuroendocrine neoplasms with or without liver metastasis
23. PD-24 A novel molecular subtype for Chinese stage II-III colorectal cancer based on multi-center and large sample size data
24. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance
25. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
26. 115P PD-L1 expression landscape and microsatellite instability status in Chinese endometrial and cervical cancer patients
27. 1408P The landscape of ROS1 fusion in patients with non-small cell lung cancer in China
28. 1253P Clinical relevance of immune factors beyond CD8+T cells and mutation status of EGFR and ALK in patients with non-small cell lung cancer
29. 498P Differences in tumor immune microenvironment and clinical outcomes between right and left colon cancer
30. 1342P Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study
31. 116P PD-L1 expression profile and microsatellite instability status in Chinese gastric cancer patients
32. LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)
33. 481P Different gene mutation of colorectal cancer was tightly associated with various types of tumor immune microenvironment
34. Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease
35. Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
36. Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement
37. A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
38. Development of a nomogram for predicting survival in microsatellite stable patients with resected colorectal cancer
39. Prognosis of three histological subtypes of colorectal adenocarcinoma: A retrospective analysis of 8005 Chinese patients
40. HER2 overexpression and amplification in patients with colorectal cancer (HOLIC): A large-scale retrospective study in Chinese population
41. 281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
42. 151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement
43. 1474P - A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
44. 121P - Prognosis of three histological subtypes of colorectal adenocarcinoma: A retrospective analysis of 8005 Chinese patients
45. 123P - Development of a nomogram for predicting survival in microsatellite stable patients with resected colorectal cancer
46. 600P - Development of a nomogram for predicting survival in microsatellite stable patients with resected colorectal cancer
47. 479TiP Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC)
48. 563P - HER2 overexpression and amplification in patients with colorectal cancer (HOLIC): A large-scale retrospective study in Chinese population
49. 158P Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis.
50. 519P Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.